Disrupting Glutamine Metabolism Slows Liver Cancer Growth
By LabMedica International staff writers Posted on 23 Jun 2016 |
Image: A fluorescent microscope image of liver cells and the chemical structure of glutamine (Photo courtesy of Dr. Kristina Schoonjans, Ecole Polytechnique Fédérale de Lausanne).
Cancer researchers used a line of genetically engineered mice to demonstrate the dependency of liver cancer cells on the amino acid glutamine as their primary energy source.
Investigators at the Ecole Polytechnique Fédérale de Lausanne (Switzerland) worked with a line of "knock-out" mice that had been genetically engineered to lack the gene for production of the enzyme LRH-1 (liver receptor homolog 1). LRH-1 is a member of the nuclear receptor family of intracellular transcription factors and plays a critical role in the regulation of development, cholesterol transport, bile acid homeostasis, and steroidogenesis.
The investigators reported in the June 1, 2016, issue of the journal Genes & Development that gain and loss of function of LRH-1 in the liver modulated the expression and activity of mitochondrial glutaminase 2 (GLS2), the first and rate-limiting step of the glutamine pathway.
Closing down this pathway by eliminating LRH-1 prevented the utilization of glutamine as a fuel and put the cancerous cells into tremendous metabolic distress. Acute and chronic deletion of LRH-1 in the liver prevented the deamination of glutamine and reduced glutamine-dependent anaplerosis (the process of replenishment of depleted metabolic cycle or pathway intermediates).
The reduction in the lysis of glutamine limited the availability of alpha-ketoglutarate, which in turn inhibited mTORC1 (mammalian target of rapamycin (mTOR) complex 1) signaling to eventually block cell growth and proliferation.
"Inhibiting LRH-1 can thus be an effective way to starve only liver cancer cells, while leaving normal cells intact," said contributing author Dr. Kristina Schoonjans, head of the laboratory of metabolic signaling at the Ecole Polytechnique Fédérale de Lausanne.
Related Links:
Ecole Polytechnique Fédérale de Lausanne
Investigators at the Ecole Polytechnique Fédérale de Lausanne (Switzerland) worked with a line of "knock-out" mice that had been genetically engineered to lack the gene for production of the enzyme LRH-1 (liver receptor homolog 1). LRH-1 is a member of the nuclear receptor family of intracellular transcription factors and plays a critical role in the regulation of development, cholesterol transport, bile acid homeostasis, and steroidogenesis.
The investigators reported in the June 1, 2016, issue of the journal Genes & Development that gain and loss of function of LRH-1 in the liver modulated the expression and activity of mitochondrial glutaminase 2 (GLS2), the first and rate-limiting step of the glutamine pathway.
Closing down this pathway by eliminating LRH-1 prevented the utilization of glutamine as a fuel and put the cancerous cells into tremendous metabolic distress. Acute and chronic deletion of LRH-1 in the liver prevented the deamination of glutamine and reduced glutamine-dependent anaplerosis (the process of replenishment of depleted metabolic cycle or pathway intermediates).
The reduction in the lysis of glutamine limited the availability of alpha-ketoglutarate, which in turn inhibited mTORC1 (mammalian target of rapamycin (mTOR) complex 1) signaling to eventually block cell growth and proliferation.
"Inhibiting LRH-1 can thus be an effective way to starve only liver cancer cells, while leaving normal cells intact," said contributing author Dr. Kristina Schoonjans, head of the laboratory of metabolic signaling at the Ecole Polytechnique Fédérale de Lausanne.
Related Links:
Ecole Polytechnique Fédérale de Lausanne
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples